AzurRx BioPharma, Inc. - FORM S-1 - EX-23.1 - CONSENT OF WEISERMAZARS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - July 13, 2016

Attached files

file filename
EX-10.1 - STOCK PURCHASE AGREEMENT DATED MAY 21, 2014 BETWEEN THE REGISTRANT, PROTEA BIOSCIENCES GROUP, INC. AND ITS WHOLLY-OWNED SUBSIDIARY, PROTEA BIOSCIENCES, INC. - AzurRx BioPharma, Inc.ex10-1.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - AzurRx BioPharma, Inc.ex21-1.htm
EX-14.1 - CODE OF ETHICS OF AZURRX BIOPHARMA, INC. APPLICABLE TO DIRECTORS, OFFICERS AND EMPLOYEES - AzurRx BioPharma, Inc.ex14-1.htm
EX-10.4 - EMPLOYMENT AGREEMENT BETWEEN THE REGISTRANT AND MR. SPOOR - AzurRx BioPharma, Inc.ex10-4.htm
EX-10.3 - AMENDED AND RESTATED AZURRX BIOPHARMA, INC. 2014 OMNIBUS EQUITY INCENTIVE PLAN - AzurRx BioPharma, Inc.ex10-3.htm
EX-10.2 - AMENDED AND RESTATED JOINT RESEARCH AND DEVELOPMENT AGREEMENT DATED JANUARY 1, 2014 BETWEEN THE REGISTRANT AND MAYOLY - AzurRx BioPharma, Inc.ex10-2.htm
EX-4.2 - FORM OF INVESTOR WARRANT - AzurRx BioPharma, Inc.ex4-2.htm
EX-3.2 - AMENDED AND RESTATED BYLAWS OF THE REGISTRANT - AzurRx BioPharma, Inc.ex3-2.htm
EX-3.1 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE REGISTRANT - AzurRx BioPharma, Inc.ex3-1.htm
S-1 - FORM S-1 - AzurRx BioPharma, Inc.azurrxs1_july2016.htm
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the use in the Prospectus constituting part of the Registration Statement on Form S-1 of our report dated June 15, 2016, related to the financial statements of Protea Europe SAS (“Predecessor”) for the period January 1, 2014 through May 31, 2014; and our report dated June 15, 2016, related to the consolidated financial statements of AzurRx BioPharma, Inc. as of December 31, 2015 and 2014 and for the year ended December 31, 2015 and the period January 30, 2014 (date of inception) through December 31, 2014 which appear in such Prospectus. The report for AzurRx BioPharma, Inc. includes an explanatory paragraph about the existence of substantial doubt concerning its ability to continue as a going concern. We also consent to the reference to our Firm under the caption “Experts” in such Prospectus.


/s/ WeiserMazars LLP
Edison, New Jersey
July 13, 2016

AzurRx BioPharma, Inc. Reports

Also read